Infective endocarditis is a disease characterized by endocardial involvement, where vegetations infected by microorganisms form on the valves, cardiac chambers, and endothelium of large blood vessels. It is potentially fatal, with an incidence of 3 to 7 cases per 100,000 people per year. Diagnosis is made according to the modified Duke criteria, which include two major and five minor criteria. The most common infectious agents are Streptococcus viridans, Streptococcus bovis, HACEK group, and Staphylococcus aureus. Streptococcus gallolycticus is a rare causative agent in infective endocarditis, occurring in 18% of cases. Colorectal cancer is almost pathognomonic, present in up to 71% of cases, and of these, 5% are associated with prosthetic valves. For colorectal cancer, blood cultures, echocardiograms, and colonoscopies are necessary. According to the evolution time of the biological prosthetic valve, it is considered early when it presents clinical symptoms within the first year and late when it presents 1 year after the replacement.

Background: Diabetes Mellitus type 2 (T2DM) is an epidemic metabolic condition that is typified by persistent hyperglycemia. Although the gold standard in the evaluation of long-term glycemic control is glycated hemoglobin (HbA1c), the polyol 1.5-anhydroglucitol (1.5-AG), a naturally occurring polyol, is reabsorbed in the renal tubules and is competitively inhibited by glucose, thus it may represent early glucose fluctuations. Change in 1.5-AG is a reflection of the variation in blood glucose over one to two weeks. Objective: The objective of the study was to establish the relationship between serum 1,5-AG and glycemic control variables (HbA1c, FBS) in T2DM patients. Materials and Methods: The study was a cases control study where 60 healthy controls were used, and 60 T2DM patients were used. 1.5-AG has been demonstrated to indicate change in blood glucose over a period of one to two weeks. An ELISA kit was used to measure serum 1, 5-AG. Fasting glucose, insulin (with a Maglumi device), insulin resistance index (HOMA-IR), renal function test (B.Urea and S.Cr) and GH-900Plus HbA1c Analyzer. Results: Serum 1.5-AG was also found to be lower in the T2DM patients than the control group (9.31 ± 4.73 mg/L vs. 22.39 + 8.20 mg/L; p<0.001). There was a considerable negative correlation between (1.5-AG and FBS, HbA 1c and HOMA-IR). The receiver operating characteristic (ROC) curve analysis indicated the diagnostic accuracy of (1.5-AG on T2DM (AUC = 0.94)) was high and the best cutoff value of 11.95mg/L offered 85.0% sensitivity and 98.3% specificity. Conclusion: It is possible to consider that 1.5-AG is a good marker to study levels in people with type 2 diabetes during the period of one to two weeks. More research will be required to ascertain the use of these chemicals in diagnosis. The blood glucose variations in the patients with T2DM. Specifically the people who are below 180mg/dl and those above 180mg/dl of blood sugar.